Merck 2010 Annual Report Download - page 77
Download and view the complete annual report
Please find page 77 of the 2010 Merck annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.-
1 -
2
-
3
-
4
-
5
-
6
-
7
-
8
-
9
-
10
-
11
-
12
-
13
-
14
-
15
-
16
-
17
-
18
-
19
-
20
-
21
-
22
-
23
-
24
-
25
-
26
-
27
-
28
-
29
-
30
-
31
-
32
-
33
-
34
-
35
-
36
-
37
-
38
-
39
-
40
-
41
-
42
-
43
-
44
-
45
-
46
-
47
-
48
-
49
-
50
-
51
-
52
-
53
-
54
-
55
-
56
-
57
-
58
-
59
-
60
-
61
-
62
-
63
-
64
-
65
-
66
-
67 -
68 -
69 -
70 -
71 -
72 -
73 -
74 -
75 -
76 -
77 -
78 -
79 -
80 -
81 -
82 -
83 -
84 -
85 -
86 -
87 -
88
-
89
-
90
-
91
-
92
-
93
-
94
-
95
-
96
-
97
-
98
-
99
-
100
-
101
-
102
-
103
-
104
-
105
-
106
-
107
-
108
-
109
-
110
-
111
-
112
-
113
-
114
-
115
-
116
-
117
-
118
-
119
-
120
-
121
-
122
-
123
-
124
-
125
-
126
-
127
-
128
-
129
-
130
-
131
-
132
-
133
-
134
-
135
-
136
-
137
-
138
-
139
-
140
-
141
-
142
-
143
-
144
-
145
-
146
-
147
-
148
-
149
-
150
-
151
-
152
-
153
-
154
-
155
-
156
-
157
-
158
-
159
-
160
-
161
-
162
-
163
-
164
-
165
-
166
-
167
-
168
-
169
-
170
-
171
-
172
-
173
-
174
-
175
-
176
-
177
-
178
-
179
-
180
-
181
-
182
-
183
-
184
-
185
-
186
-
187
-
188
-
189
-
190
-
191
-
192
-
193
-
194
-
195
-
196
-
197
-
198
-
199
-
200
-
201
-
202
-
203
-
204
-
205
-
206
-
207
-
208
-
209
-
210
-
211
-
212
-
213
-
214
-
215
-
216
-
217
-
218
-
219
-
220
-
221
-
222
-
223
 |
 |
the work in-house. We provide services to identify disease targets and better understand how to
improve the efficacy of drugs on targeted patient groups and prevent side effects.
Merck Millipore’s service offering helps customers better understand the safety and efficacy
of biologic drugs and vaccines. With the increasing development of biologics, companies
are leveraging our expertise to help them evaluate the efficacy of these drugs. We offer our
customers a broad range of services to assist with evaluating and advancing these therapeutics
from the drug development pipeline to the market. The offering includes biomarker analytical
services, assay transfer/development, validation and sample analysis, pharmacokinetics, toxico-
kinetics, immunogenicity, biological potency, and vaccine services.
The Lab Solutions Business Unit supplies products for research, analytical and clinical laborato-
ries in a wide variety of industries. Accounting for about 40% of the division’s total revenues, it
is one of the leading suppliers of laboratory chemicals, lab water equipment and consumables.
Merck Millipore has a strong track record of developing packaging concepts and chemical
packaging that protect high-quality solvents prior to use. In addition, the division is the leading
supplier of lab water and water treatment technologies.
For inorganic chemistry, we offer reagents of high purity such as salts, acids, caustics, volumetric
solutions, buffers, reference materials for instrumental analysis and products for inorganic
trace analysis. For organic chemistry, we supply a full range of basic products for synthesis,
including building blocks, reagents and solvents most commonly used in organic synthesis
from laboratory scale to bulk production.
As a supplier of chromatography products, Merck Millipore is also advancing the development
of analytical separation technologies. The product focus is on analytical high-performance
liquid chromatography (HPLC) and innovations to the monolithic Chromolith ® HPLC columns
for ultrafast separations.
Company 73Management Report Corporate governance Consolidated Financial Statements More information
Merck Millipore